Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

1 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-003001-94-SK (EUCTR)	06/11/2019	13/09/2019	Use of GLP-1 analogs in the treatment of multiple sclerosis	Use of GLP-1 analogs in the treatment of multiple sclerosis - MSGLP	Our hypothesis is that patients with MS have a disorder of energy metabolism in neurons and glial cells of the CNS, contributing to the development and progression of demyelinating foci and neurodegeneration, and manifested by insulin resistance in both peripheral tissues and the CNS. MedDRA version: 21.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere . Product Name: Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere	Lekárska fakulta UK Bratislava	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 2	Slovakia